Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Iproniazid→

Iproniazid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
54-92-2
Molecular formula
C9H13N3O
Molecular weight
179.22 g/mol
Drug class
Hydrazine-derived monoamine oxidase inhibitor (MAOI)historical antidepressant and antitubercular agent
Mechanism of action
Irreversibly inhibits monoamine oxidase, reducing breakdown of serotonin, noradrenaline and dopamine and increasing monoaminergic neurotransmission. The same non-selective MAO inhibition contributes to clinically significant interactions and toxicity.
Indications / reported uses
  • Historically introduced for treatment of depressive illness and originally used as an antitubercular agent. It is no longer a routine contemporary antidepressant because of serious hepatotoxicity and other safety concerns; this entry is historical pharmacology, not a current treatment recommendation.

Sources: https://pubmed.ncbi.nlm.nih.gov/19442174/ · https://www.cambridge.org/core/journals/acta-neuropsychiatrica/article/brief-history-of-antidepressant-drug-development-from-tricyclics-to-beyond-ketamine/B5C9D55C6299BC41B237187DB609DB68 · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Hydrazine-derived monoamine oxidase inhibitor (MAOI); historical antidepressant and antitubercular agent

Mechanism of action

Irreversibly inhibits monoamine oxidase, reducing breakdown of serotonin, noradrenaline and dopamine and increasing monoaminergic neurotransmission. The same non-selective MAO inhibition contributes to clinically significant interactions and toxicity.

General use cases

  • Historically introduced for treatment of depressive illness and originally used as an antitubercular agent. It is no longer a routine contemporary antidepressant because of serious hepatotoxicity and other safety concerns; this entry is historical pharmacology, not a current treatment recommendation.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Iproniazid Environmental Risk Assessment (ERA) (the Iproniazid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.